中裕新药,TaiMed Biologics,  
中裕新药股份有限公司(原宇昌生技)成立于2007年9月。本公司以成为世界创新技术为基础的生物科技新药开发公司为目标，从事治疗及预防感染性疾病的新药研发。现有主要股东包括润泰集团、国发基金、合一创投及上智创投。
2007年中裕从美国Gennentech公司取得全球市场独家授权，技术移转一个治疗爱滋病的单株抗体生物制剂TMB-355(lbalizumab)，并持续在美国进行第二个临床二期的试验，预计2010年底完成所有病人的疗程及数据分析。另外，中裕于2008年正式进驻于位于南港的中央研究院育成中心，设立实验室。并于年底与中央研究院签「独家授权协议」，技术移转治疗流行性感冒药物零流感，并继续其制程 ??及临床试验的开发。
中裕新药初期的研究发展将着重于TMB-355及后续药物的临床试验开发及技术移转，药物标的物的搜寻、验证，生物功能的探讨，以及新产品开发的可行性评估。由于爱滋病新药TMB-355即将完成临床二期试验，且初期的数据证明疗效，中裕在公司短期及中期的经营策略上，保有相当的弹性。

创办人
TMB创办于2007年9月4日，其目的是为在台湾创造一家世界级的、以创新为基础的生物技术公司。

创办人如下：
何大一博士
中研院院士，中裕新药最高技术咨询顾问及前任董事。何博士是25年来世界AIDS研究的主要权威人士，发表论文超过350篇。现为美国Aaron Diamond AIDS研究中心主任及CEO，洛克菲勒大学Irene Diamond执行长。他捍卫的高效抗逆转录病毒疗法能前所未有地控制病患的HIV病毒。何博士的诸多荣誉中，包括入选美国艺术与科学院、美国国家科学院医学研究所、台湾中央研究院、中国科学院。
陈良博博士
中研院院士，哈佛大学荣誉教授，现为中裕新药美国子公司(TMB USA Inc)董事长。
蔡英文博士
台湾行政院前副院长，前陆委会主委，为本公司第一任董事长

TaiMed Biologics was formed on September 4, 2007 to realize the vision of creating a world-class, innovation-based biotechnology company that will satisfy the unmet medical needs of patients around the world. The company signed an agreement with Genentech for the licensing of Ibalizumab shortly after its formation. This drug candidate, also known as TMB-355, is a proprietary humanized anti-CD4 monoclonal antibody for the treatment of HIV/AIDS. A phase-2b clinical trial is currently underway and we expect the trial to be completed in Q1 2011.
TaiMed Biologics has made much progress in its short existence. An outstanding management team with industry experience has been assembled in both Taiwan and the US. TMB is committed to evaluating new business development opportunities. In Q4 of 2008, TMB in-licensed Tamiphosphor, a neuraminidase inhibitor for the treatment of influenza, from Academia Sinica in Taiwan and has taken that program forward. In early 2009, drug synthesis work has been conducted as well as a collaboration with NIH has been established for cross resistance testing. In addition, in collaboration with the Aaron Diamond AIDS Research Center, the development of Ibalizumab for prevention of HIV infection will be explored in a phase 1 trial in 2H 2010. This project has received grant funding from the Bill and Melinda Gates Foundation.
TaiMed Biologics is committed to conducting business with integrity and passion. We remain to be forward-thinking and utilize our resources wisely and efficiently in order to meet our long-term objectives.